|Bid||95.00 x 1000|
|Ask||114.00 x 800|
|Day's Range||112.64 - 113.96|
|52 Week Range||80.69 - 114.02|
|PE Ratio (TTM)||51.04|
|Earnings Date||Oct 29, 2018 - Nov 2, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||112.33|
Masimo announced today the findings of a recently published study in which researchers investigated whether home pulse oximetry monitoring might be a useful initial screening method of determining which children with Down syndrome – who are at high risk of obstructive sleep apnea – be recommended to undergo multichannel sleep studies to diagnose the condition.
On a relative basis, the sector continues to digest its strong year-to-date gains and work off a bearish momentum divergence by consolidating above our previous price objective at 0.734. An individual name in the sector breaking out is Masimo Corporation ( MASI). It has been consolidating for the past 18 months, and this push to new all-time highs signals the resumption of its long-term uptrend.
Masimo (MASI), a global medical technology developer and manufacturer of innovative noninvasive patient monitoring technologies, announced today that H Michael Cohen, former Vice Chairman of Healthcare Investment Banking at Deutsche Bank Securities, has been elected to Masimo’s Board of Directors. Over the past 19 years, he has held various roles at Deutsche Bank, including Global Head, Healthcare Investment Banking and most recently Vice Chairman, Healthcare Investment Banking. Prior to joining Deutsche Bank, Mr. Cohen worked at SG Cowen, Union Bank of Switzerland, and Booz Allen Hamilton.
The maker of non-invasive monitoring technologies posts strong revenue and adjusted earnings growth, thanks to high demand for its pulse oximetry devices.
Masimo (MASI) delivered earnings and revenue surprises of 1.39% and 1.74%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Irvine, California-based company said it had profit of 79 cents. Earnings, adjusted for one-time gains and costs, came to 73 cents per share. The results topped Wall Street expectations. ...
Masimo announced today the findings of a recently published study in which researchers at Dartmouth-Hitchcock Medical Center investigated the impact of an integrated clinical monitoring system, using various Masimo technologies and devices, on clinical workflow and patient care in the general ward.
OPKO Health's (OPK) partner VFMCRP gets regulatory nod from Health Canada to market flagship RAYALDEE; benefits patients diagnosed with chronic kidney disease.
On Tuesday, July 17, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Six out of nine sectors ended Tuesday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Medical Appliances & Equipment equities this morning: AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX), Masimo Corp. (NASDAQ: MASI), Medtronic PLC (NYSE: MDT), and MiMedx Group Inc. (NASDAQ: MDXG).
Masimo announced today the findings of a recently published study in which researchers at Kocaeli University in Turkey compared the performance of conventional fluid management to goal-directed fluid management using Masimo PVi® in patients undergoing elective colorectal surgery.
Masimo announced today the worldwide release of the Vital Signs Check Application, an integrated patient data collection and workflow application for the Masimo Root® patient monitoring and connectivity platform.
Masimo's (MASI) and STERIS' (STE) strong expected growth rates and impressive price performance make them close contenders in the Medical Instruments space.